A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2017
At a glance
- Drugs SGM 101 (Primary)
- Indications Colon cancer; Pancreatic cancer; Rectal cancer
- Focus Adverse reactions
- Sponsors SurgiMAb
- 12 May 2017 Planned End Date changed from 1 Mar 2017 to 31 Jan 2018.
- 12 May 2017 Planned primary completion date changed from 1 Jan 2017 to 31 Oct 2017.
- 29 Nov 2016 New trial record